Preliminary evaluation of the cytotoxicity of a series of tris-2-aminoethylamine (Tren) based hexadentate heterocyclic donor agents.

[1]  M. Brechbiel,et al.  Role of zinc and iron chelation in apoptosis mediated by tachpyridine, an anti-cancer iron chelator. , 2004, Biochemical pharmacology.

[2]  Nickel(II), copper(II) and zinc(II) binding properties and cytotoxicity of tripodal, hexadentate tris(ethylenediamine)--analogue chelators. , 2004, Dalton transactions.

[3]  M. Walsh,et al.  Transferrin receptor expression by human bladder transitional cell carcinomas , 1987, Urological Research.

[4]  C. N. Coleman,et al.  Evaluation of copper chelation agents as anti-angiogenic therapy. , 2003, Bioorganic & medicinal chemistry.

[5]  M. Brechbiel,et al.  Steric effects caused by N-alkylation of the tripodal chelator N,N′,N″-tris(2-pyridylmethyl)-cis,cis-1,3,5-triaminocyclohexane (tachpyr): structural and electronic properties of the Mn(II), Co(II), Ni(II), Cu(II) and Zn(II) complexes , 2003 .

[6]  D. Richardson,et al.  Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  M. Brechbiel,et al.  Novel chelating agents for potential clinical applications of copper. , 2002, Nuclear medicine and biology.

[8]  M. Brechbiel,et al.  Synthesis of novel 1,3,5- cis , cis -triaminocyclohexane ligand based Cu(II) complexes as potential radiopharmaceuticals and correlation of structure and serum stability , 2001 .

[9]  M. Willingham,et al.  p53-independent apoptosis mediated by tachpyridine, an anti-cancer iron chelator. , 2001, Carcinogenesis.

[10]  Jean‐Didier Maréchal,et al.  Amine conformational change and spin conversion induced by metal-assisted ligand oxidation: from the seven-coordinate iron(II)–TPAA complex to the two oxidized iron(II)–(py)3tren isomers. Characterization, crystal structures, and density functional study , 2000 .

[11]  M. Brechbiel,et al.  Novel iron complexes and chelators based on cis,cis-1,3,5-triaminocyclohexane: iron-mediated ligand oxidation and biochemical properties , 1998, JBIC Journal of Biological Inorganic Chemistry.

[12]  M. Brechbiel,et al.  Tumor cell cytotoxicity of a novel metal chelator. , 1998, Blood.

[13]  M. Brechbiel,et al.  An improved synthesis of cis,cis-1,3,5-triaminocyclohexane. Synthesis of novel hexadentate ligand derivatives for the preparation of gallium radiopharmaceuticals , 1996 .

[14]  D. Richardson,et al.  The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. , 1995, Blood.

[15]  R. Rubin,et al.  Antitumor effect of deferoxamine on human hepatocellular carcinoma growing in athymic nude mice , 1992, Cancer.

[16]  M. Hirobe,et al.  Novel iron complexes behave like superoxide dismutase in vivo. , 1991, Free radical research communications.

[17]  J. Kemp,et al.  Synergistic inhibition of lymphoid tumor growth in vitro by combined treatment with the iron chelator deferoxamine and an immunoglobulin G monoclonal antibody against the transferrin receptor. , 1990, Blood.

[18]  J. Verkade,et al.  New Prophosphatranes: Novel intermediates to five‐coordinate phosphatranes , 1989 .

[19]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[20]  W. Faulk,et al.  TRANSFERRIN AND TRANSFERRIN RECEPTORS IN CARCINOMA OF THE BREAST , 1980, The Lancet.